Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its pipeline candidate, ZG006, which is under development for the treatment of small-cell lung cancer (SCLC).
ZG006 is a tri-specific antibody that has been developed using Zelgen’s proprietary bispecific (BsAb)/multi-specific antibody platform. The drug targets CD3 and two distinct DLL3 epitopes, which are associated with SCLC. Preclinical studies have demonstrated that ZG006 exhibits significant anti-tumor activity and possesses favorable safety profiles.- Flcube.com
